Citable filing context
VTRS's research view summarizes recent SEC filing context, starting with earnings from Aug 6, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 6, 2026 | earnings | Viatris reported Q2 2026 total revenues of $3.8 billion and raised its full-year 2026 financial guidance. |
| Jul 1, 2026 | debt_offering | Viatris entered into an amended ¥40 billion senior unsecured term loan credit agreement with Mizuho Bank. |
| Jun 18, 2026 | debt_offering | Viatris completed a public offering of €650 million in 4.250% Senior Notes due 2033. |
| Aug 6, 2026 | Guidance: adjusted_ebitda | 4300.00 to 4500.00 |
| Aug 6, 2026 | Guidance: adjusted_eps | 2.45 to 2.59 |
| Aug 6, 2026 | Guidance: free_cash_flow_excluding_transaction_and_restructuring_costs | 2050.00 to 2350.00 |
| Aug 6, 2026 | mda_quarterly | Viatris reported total revenues of $3.76 billion for the second quarter of 2026, a 5% increase year-over-year, driven by new product launches and base business growth in Greater China. Despite this top-line growth, the company recorded a net loss of $118.8 million for the quarter, impacted by a $177.8 million charge related to the planned sale of Tyrvaya® product rights and ongoing restructuring expenses. The company is currently executing an enterprise-wide strategic review (EWSR) initiated in 2025, targeting a 10% global workforce reduction and total pre-tax restructuring charges of $700 million to $850 million. Operational challenges persist, notably at the Nashik, India, manufacturing facility, where a February 2026 fire and subsequent FDA Form 483 observations have caused supply disruptions expected to impact second-half 2026 revenues by $100 million to $150 million. Viatris continues to manage significant legal and regulatory matters, including ongoing antitrust litigation in the U.S. and Canada regarding generic drug pricing, with trials scheduled through 2028. The company maintains a disciplined capital allocation strategy, having repurchased approximately 103.5 million shares for $1.15 billion through June 30, 2026, and continues to navigate complex intellectual property landscapes for key products like Amitiza® and dimethyl fumarate. |
| May 7, 2026 | mda_quarterly | Viatris reported first-quarter 2026 total revenues of $3.52 billion, an 8% increase over the prior year, with constant currency net sales growing 3%. Growth was primarily driven by an 18% constant currency increase in Greater China and new product launches in Developed Markets. Net earnings reached $176.4 million, a significant recovery from the $3.04 billion loss in Q1 2025, which was driven by a $2.94 billion goodwill impairment. Key revenue contributors include Lipitor, Norvasc, and Lyrica. The company is implementing a 2026 Restructuring Program targeting a 10% workforce reduction, with expected pre-tax charges between $700 million and $850 million and projected savings of $600 million to $700 million. Viatris also liquidated its Biocon Biologics equity stake for $815 million. Critical operational risks include an FDA import alert at the Indore facility affecting 11 products and a February 2026 fire at the Nashik plant, which incurred a $71.9 million charge. Legal headwinds include ongoing drug pricing MDL litigation and a $335 million opioid settlement framework. The company maintains $1.80 billion in cash and remains in compliance with its 3.75x maximum leverage ratio covenant. |
Source: SEC EDGAR filing text and events; period Aug 6, 2026; filed Aug 6, 2026.
VTRS company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.